Literature DB >> 24853830

Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation.

Toshiyuki Nagai1, Shun Kohsaka2, Shigeo Okuda3, Toshihisa Anzai4, Koichiro Asano5, Keiichi Fukuda2.   

Abstract

BACKGROUND: Cardiac death is the leading cause of mortality associated with sarcoidosis in Japan. However, the involvement of sarcoidosis infiltration often remains undetected. Recently, late gadolinium enhancement with cardiovascular MRI (LGE-CMR) imaging has been introduced for the detection of myocardial infiltrative disease, as it enables the detection of even minor myocardial damage. We investigated the incidence and prognostic value of LGE-CMR in patients with extracardiac sarcoidosis without cardiac manifestations.
METHODS: Sixty-one consecutive patients who met the histologic and clinical criteria for sarcoidosis, and who did not have signs or symptoms of cardiovascular involvement, were prospectively recruited. LGE-CMR was performed at the time of enrollment, and patients were classified into positive or negative late gadolinium enhancement groups based on the findings. The study end point was a composite of all-cause death, symptomatic arrhythmia, and heart failure necessitating admission.
RESULTS: Patients were predominantly middle aged (57 ± 15 years) and female (66%), and most had stable disease activity that did not require treatment with immunosuppressants. LGE-CMR detected cardiac involvement in eight patients (13%). Interventricular septal thinning detected by echocardiography was an independent predictor of LGE-CMR-detected cardiac involvement. During the follow-up period of 50 ± 12 months, no significant difference in adverse events was noted between patients in the LGE-CMR-positive and LGE-CMR-negative groups.
CONCLUSIONS: LGE-CMR detected cardiac involvement in 13% of patients with sarcoidosis without cardiac manifestation, but both patients with and without LGE had relatively low event rates. TRIAL REGISTRY: Japan Primary Registries Network; No.: UMIN000001549; URL: www.umin.ac.jp.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24853830     DOI: 10.1378/chest.14-0139

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

Review 1.  Role of Imaging Techniques for Diagnosis, Prognosis and Management of Heart Failure Patients: Cardiac Magnetic Resonance.

Authors:  Jorge A Gonzalez; Christopher M Kramer
Journal:  Curr Heart Fail Rep       Date:  2015-08

2.  Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.

Authors:  Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2017-10       Impact factor: 5.952

3.  Cardiac sarcoidosis: a challenging diagnosis.

Authors:  Maria Vincenza Polito; Stephan Stoebe; Leonard Leifels; Patrick Stumpp; Kilian Solty; Gennaro Galasso; Federico Piscione; Ulrich Laufs; Karin Klingel; Andreas Hagendorff
Journal:  Clin Res Cardiol       Date:  2018-05-18       Impact factor: 5.460

4.  A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology.

Authors:  Riemer H J A Slart; Andor W J M Glaudemans; Patrizio Lancellotti; Fabien Hyafil; Ron Blankstein; Ronald G Schwartz; Wael A Jaber; Raymond Russell; Alessia Gimelli; François Rouzet; Marcus Hacker; Olivier Gheysens; Sven Plein; Edward J Miller; Sharmila Dorbala; Erwan Donal
Journal:  J Nucl Cardiol       Date:  2018-02       Impact factor: 5.952

5.  Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring.

Authors:  Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein
Journal:  J Nucl Med       Date:  2017-08       Impact factor: 10.057

Review 6.  Update on Treatment in Cardiac Sarcoidosis.

Authors:  Laura Young; Brett W Sperry; Rory Hachamovitch
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-06

Review 7.  Advanced imaging of cardiac sarcoidosis.

Authors:  Chadi Ayoub; Elena Pena; Hiroshi Ohira; Alexander Dick; Eugene Leung; Pablo B Nery; David Birnie; Rob S B Beanlands
Journal:  Curr Cardiol Rep       Date:  2015       Impact factor: 2.931

Review 8.  Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis.

Authors:  G Cameron Coleman; Peter W Shaw; Pelbreton C Balfour; Jorge A Gonzalez; Christopher M Kramer; Amit R Patel; Michael Salerno
Journal:  JACC Cardiovasc Imaging       Date:  2016-07-20

9.  Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis.

Authors:  Tomas Vita; David R Okada; Mahdi Veillet-Chowdhury; Paco E Bravo; Erin Mullins; Edward Hulten; Mukta Agrawal; Rachna Madan; Viviany R Taqueti; Michael Steigner; Hicham Skali; Raymond Y Kwong; Garrick C Stewart; Sharmila Dorbala; Marcelo F Di Carli; Ron Blankstein
Journal:  Circ Cardiovasc Imaging       Date:  2018-01       Impact factor: 7.792

Review 10.  Clinical Features and Diagnosis of Cardiac Sarcoidosis.

Authors:  Claudio Tana; Cesare Mantini; Iginio Donatiello; Luciano Mucci; Marco Tana; Fabrizio Ricci; Francesco Cipollone; Maria Adele Giamberardino
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.